Italia markets close in 6 hours 2 minutes

Vigil Neuroscience, Inc. (VIGL)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
2,5800-0,1900 (-6,86%)
Alla chiusura: 04:00PM EDT
2,5900 +0,01 (+0,39%)
Dopo ore: 07:26PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente2,7700
Aperto2,7600
Denaro2,5200 x 100
Lettera2,7200 x 100
Min-Max giorno2,5450 - 2,8100
Intervallo di 52 settimane2,5300 - 11,1100
Volume66.652
Media Volume89.204
Capitalizzazione96,967M
Beta (5 anni mensile)1,78
Rapporto PE (ttm)N/D
EPS (ttm)-2,1300
Prossima data utiliN/D
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1A16,75
  • GlobeNewswire

    Vigil Neuroscience to Present at Jefferies Inaugural Biotech CNS/Neuro Summit

    WATERTOWN, Mass., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that Ivana Magovčević-Liebisch, Ph.D., J.D., President and Chief Executive Officer, and David Gray, Ph.D., Chief Science Officer, will participate in a fireside chat at the Jefferies Inaugural Biotech CNS/Neuro Summit on Thursday, October 12, 2023, at 1:30

  • GlobeNewswire

    Vigil Neuroscience Receives Positive Opinion from European Medicines Agency on Orphan Drug Designation for VGL101 for the Treatment of ALSP

    WATERTOWN, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) has issued a positive opinion on the Company’s application for orphan drug designation for VGL101 for the treatment of CSF1R-related leukoencephalopathy, which

  • GlobeNewswire

    Vigil Neuroscience Presents VGL101 Complete Phase 1 Data and Phase 2 IGNITE Trial Design at the 2023 American Neurological Association Annual Meeting

    - Complete Phase 1 data analysis demonstrated that VGL101 continued to have a favorable safety and tolerability profile and proof-of-target engagement in SAD/MAD cohorts up to 60 mg/kg - - On track to report 6-month interim data from IGNITE trial in Q4 2023 from first 6 patients who have received 20 mg/kg of VGL101 - WATERTOWN, Mass., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia f